Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;103(5):e14534.
doi: 10.1111/cbdd.14534.

Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy

Krisyanti Budipramana  1 , Frangky Sangande  2
Affiliations
Review

Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy

Krisyanti Budipramana et al. Chem Biol Drug Des. 2024 May.

Abstract

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor 2 (VEGFR2) are known as valid targets for cancer therapy. Overexpression of EGFR induces uncontrolled cell proliferation and VEGF expression triggering angiogenesis via VEGFR2 signaling. On the other hand, VEGF expression independent of EGFR signaling is already known as one of the mechanisms of resistance to anti-EGFR therapy. Therefore, drugs that act as dual inhibitors of EGFR and VEGFR2 can be a solution to the problem of drug resistance and increase the effectiveness of therapy. In this review, we summarize the relationship between EGFR and VEGFR2 signal transduction in promoting cancer growth and how their kinase domain structures can affect the selectivity of an inhibitor as the basis for designing dual inhibitors. In addition, several recent studies on the development of dual EGFR and VEGFR2 inhibitors involving docking simulations were highlighted in this paper to provide some references such as pharmacophore features of inhibitors and key residues for further research, especially in computer-aided drug design.

Keywords: EGFR; VEGFR2; cancer; dual inhibitor; pharmacophore.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Al‐Muntaser, S. M., Al‐Karmalawy, A. A., El‐Naggar, A. M., Ali, A. K., Abd El‐Sattar, N. E. A., & Abbass, E. M. (2023). Novel 4‐thiophenyl‐pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR‐2: Design, synthesis, biological evaluations, and in silico studies. RSC Advances, 13, 12184–12203. https://doi.org/10.1039/d3ra00416c
    1. Aly, R. M., Serya, R. A. T., El‐Motwally, A. M., Esmat, A., Abbas, S., & Abou El Ella, D. A. (2017). Novel quinoline‐3‐carboxamides (part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity. Bioorganic Chemistry, 75, 368–392. https://doi.org/10.1016/j.bioorg.2017.10.018
    1. Amin, K. M., Barsoum, F. F., Awadallah, F. M., & Mohamed, N. E. (2016). Identification of new potent phthalazine derivatives with VEGFR‐2 and EGFR kinase inhibitory activity. European Journal of Medicinal Chemistry, 123, 191–201. https://doi.org/10.1016/j.ejmech.2016.07.049
    1. Azzi, S., Hebda, J. K., & Gavard, J. (2013). Vascular permeability and drug delivery in cancers. Frontiers in Oncology, 3, 211. https://doi.org/10.3389/fonc.2013.00211
    1. Bakr, R. B., Mehany, A. B. M., & Abdellatif, K. R. A. (2017). Synthesis, EGFR inhibition and anti‐cancer activity of new 3,6‐dimethyl‐1‐phenyl‐4‐(substituted‐methoxy)pyrazolo[3,4‐d] pyrimidine derivatives. Anti‐Cancer Agents in Medicinal Chemistry, 17, 1389–1400. https://doi.org/10.2174/1872211311666170213105004

Publication types

MeSH terms